Low-Density Lipoprotein (LDL) Cholesterol, Beta-Quantification, Serum
Use
This test is useful for evaluating cardiovascular risk, verifying estimated low-density lipoprotein cholesterol (LDL-C) in patients with hypertriglyceridemia or very low LDL-C, and diagnosing familial hypobetalipoproteinemia and abetalipoproteinemia. LDL-C is causally related to atherosclerotic cardiovascular disease and remains a primary focus for assessing cardiovascular risk and effectiveness of treatments like diet and pharmacologic therapy.
Special Instructions
Not provided.
Limitations
Results can be falsely decreased in patients with elevated levels of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, N-acetylcysteine (NAC), and metamizole. Gross hemolysis and gross icterus can cause specimen rejection. Extremely low LDL-C concentrations are associated with conditions like abetalipoproteinemia and hypobetalipoproteinemia, which can present complications such as fat malabsorption.
New York Approved
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
Low-Density Lipoprotein Cholesterol
Analyte
LOINC Codes
- 18261-8 - LDLc SerPl.Ultracent-mCnc
- 18261-8 - LDLc SerPl.Ultracent-mCnc
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
2 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into plastic vial. Send refrigerated.
Causes for Rejection
Gross hemolysis and gross icterus will lead to rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 10 days |
| Frozen | 60 days |